Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | TSHR | P16473 | 3/20 | 0.55 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.50 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.43 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.43 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methyl Alcohol SCHEMBL28671424 | 0.92 | ALDH1A1 (0.54) | ALDH1A1TSHRAOC3CA2KDM4E | |
| SCHEMBL1376791 | 0.84 | HRH3 (0.41) | ALDH1A1TSHRAOC3PYCR1IDO1 | |
| SCHEMBL7814373 | 0.82 | ALDH1A1 (0.55) | ALDH1A1TSHRAOC3CALM1CA2 | |
| SCHEMBL4079504 | 0.80 | ALDH1A1 (0.67) | ALDH1A1TSHRAOC3CA2KDM4E | |
| Hydrochloric Acid SCHEMBL28417225 | 0.78 | ALDH1A1 (0.50) | ALDH1A1TSHRAOC3CA2SMN1; SMN2 | |
| SCHEMBL28274495 | 0.78 | AOC3 (0.58) | ALDH1A1TSHRAOC3CALM1CA2 | |
| SCHEMBL423416 | 0.78 | ALDH1A1 (0.50) | ALDH1A1TSHRAOC3CALM1CA2 | |
| Hydrochloric Acid SCHEMBL27259243 | 0.78 | ALDH1A1 (0.64) | ALDH1A1TSHRAOC3CA2KDM4E | |
| SCHEMBL81123 | 0.78 | ALDH1A1 (0.45) | ALDH1A1TSHRAOC3CA2KDM4E | |
| SCHEMBL28028861 | 0.78 | TSHR (0.50) | ALDH1A1TSHRAOC3CA2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12337036-B2 | Compounds and methods for trans-membrane delivery of molecules | APOSENSE LTD (IL) | 2025-06-24 | — | — | US | claimed |
| CN-114369070-B | Preparation process of rufinamide | 海南医学院 | 2023-04-14 | — | — | CN | claimed |
| CN-114369070-A | Preparation process of rufinamide | 海南医学院 | 2022-04-19 | — | — | CN | claimed |
| CN-215440287-U | Post-treatment device for difluorobenzylamine and trifluorobenzylamine | 弈柯莱(台州)药业有限公司 | 2022-01-07 | — | — | CN | claimed |
| US-20210052736-A1 | COMPOUNDS AND METHODS FOR TRANS-MEMBRANE DELIVERY OF MOLECULES | APOSENSE LTD (IL) | 2021-02-25 | — | — | US | claimed |
| EP-3735276-A1 | COMPOUNDS AND METHODS FOR TRANS-MEMBRANE DELIVERY OF MOLECULES | Aposense Ltd. (IL) | 2020-11-11 | — | — | EP | claimed |
| CN-111615404-A | Compounds and methods for transmembrane delivery of molecules | 艾博森斯有限公司 | 2020-09-01 | — | — | CN | claimed |
| EP-3089969-A2 | INHIBITORS OF 17BETA-HYDROXYSTEROID DEHYDROGENASES TYPE 1 AND TYPE 2 | Elexopharm GmbH (DE) | 2016-11-09 | — | — | EP | claimed |
| EP-1155001-A4 | ISOQUINOLINE DERIVATIVES AND ISOQUINOLINE COMBINATORIAL LIBRARIES | LION BIOSCIENCE AG (DE) | 2003-05-28 | — | — | EP | claimed |
| EP-1155001-A1 | ISOQUINOLINE DERIVATIVES AND ISOQUINOLINE COMBINATORIAL LIBRARIES | TREGA BIOSCIENCES, INC. (US) | 2001-11-21 | — | — | EP | claimed |
| WO-2000050406-A1 | ISOQUINOLINE DERIVATIVES AND ISOQUINOLINE COMBINATORIAL LIBRARIES | LION BIOSCIENCE AG (DE) | 2000-08-31 | — | — | WO | claimed |
| US-12337036-B2 | Compounds and methods for trans-membrane delivery of molecules | APOSENSE LTD (IL) | 2025-06-24 | — | — | US | disclosed |
| EP-4526303-A1 | N6-ADENOSINE-METHYLTRANSFERASE PROTACS AND METHODS OF USE THEREOF | University of Zurich (CH) | 2025-03-26 | — | — | EP | disclosed |
| CN-117327091-A | Synthesis method of Rayleigh Lu Geli | 浙江天宇药业股份有限公司 | 2024-01-02 | — | — | CN | disclosed |
| WO-2023222762-A1 | N6-ADENOSINE-METHYLTRANSFERASE PROTACS AND METHODS OF USE THEREOF | UNIVERSITY OF ZURICH (CH) | 2023-11-23 | — | — | WO | disclosed |
| WO-2001025200-A1 | CYCLIC AMINE COMPOUNDS AS CCR5 ANTAGONISTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-04-12 | — | — | WO | disclosed |
| EP-0427445-A1 | Benzylideneaminoxyalkanoic acid (thio) amide derivative, process for preparing the same and herbicide | UBE INDUSTRIES, LTD. (JP) | 1991-05-15 | — | — | EP | disclosed |
| US-4728646-A | ANTITHROMBOTICS | DR. KARL THOMAE GMBH (DE) | 1988-03-01 | — | — | US | disclosed |
| US-4690923-A | ANTITHROMBOTICS | KARL THOMAE GMBH (DE) | 1987-09-01 | — | — | US | disclosed |
| US-4518596-A | Antithrombotic use of 2-(perhydro-1,4-diazino)-pyrimido (5,4,D)-pyrimidines | DR. KARL THOMAE GMBH (DE) | 1985-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12337036-B2 | Compounds and methods for trans-membrane delivery of molecules | LDLR, NPC1L1, ABCB4 | ALDH1A1 1573/4885TSHR 2243/4885AOC3 3880/4885 |
| US-20210052736-A1 | COMPOUNDS AND METHODS FOR TRANS-MEMBRANE DELIVERY OF MOLECULES | LDLR, NPC1L1, ABCB4 | ALDH1A1 1573/4885TSHR 2243/4885AOC3 3880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.